Since Judah Folkman first described the process of angiogenesis in 1971, much has been learned about the cells, the extracellular factors, and the signaling pathways that modulate the angiogenesis, arteriogenesis, and vasculogenesis.1 Promising preclinical studies led to trials of angiogenic factors and cell therapies for peripheral arterial disease (PAD) in the last 2 decades.2,3 Early stage trials have provided evidence for safety and bioactivity; however, the field still awaits a positive phase 3 pivotal trial. In this review, we will provide an outline regarding the vascular response to ischemia in animal models and in humans. We will discuss what has been learned from the clinical trials of cell therapy and angiogenic factors.
for PAD. We will conclude with recommendations for those who wish to develop regenerative therapies in the treatment of PAD.

Vascular Response to Metabolic Demand
Ischemia defines a state in which blood flow is insufficient to meet metabolic demands. This condition occurs regularly, but transiently, in healthy humans when they begin to exercise.\(^4\) In response to exercise, homeostatic mechanisms are activated so that vascular supply increases to match metabolic demand.\(^3\) Specifically, the tissue requirements for oxygen and nutrients are matched by the inflow of oxygenated blood. In addition, venous and lymphatic outflow balance the arterial inflow, so as to remove metabolites from active tissues. As the tissue becomes more metabolically active, arterial inflow and venous/lymphatic outflow increase.\(^5\) For example, at rest, the skeletal muscles of the leg require a blood flow of ≈5 mL/min per milligram of tissue. With physical exertion, such as running on a treadmill, blood flow to the lower limbs may increase 5-fold to match metabolic demand.\(^5\) This vascular response is tightly regulated by neuronal, hormonal, endothelial, and metabolic mechanisms.

Functional Responses to Metabolic Demand
In the exercising leg muscle, the arterioles dilate, reducing vascular resistance. This vasodilation is largely because of accumulation of tissue metabolites in the active muscle. Chief among these vasodilator metabolites is adenosine, which stimulates purinergic receptors on vascular smooth muscle to induce relaxation.\(^6\) Adenosine accumulation is because of the increased utilization of adenosine triphosphate during muscular contraction. Thus vascular resistance (and blood flow) is tightly coupled to metabolic activity. Other factors which accumulate with active metabolism, and which can also induce a direct vasodilation of the vascular smooth muscle, include extracellular potassium, hydrogen ions, and lactic acid.\(^7\) Humoral, nervous, and endothelial regulation play less of a role in regulating microvascular tone during exercise. However, these factors predominantly regulate the response of the conduit and collateral arteries that subserve the active tissue.

As arterioles relax in the exercising exercising leg muscle, vascular resistance drops, increasing blood flow through the larger conduit arteries of the leg. This increase in flow causes an increase in vascular shear stress. This tractive force of blood flow stimulates the endothelium to release several vasodilator factors, including nitric oxide, prostacyclin, and endothelium-dependent hyperpolarizing factor.\(^8\) The conduit arteries then vasodilate to accommodate the increase in blood flow. Other factors contribute secondarily to vasodilatation of the limb conduit arteries. These include a reduction in sympathetic nerve outflow to the limb arteries (thereby reducing any vasoconstriction because of \(\alpha\)-adrenergic receptors) and an increase in circulating epinephrine (which stimulates a vasodilation mediated by \(\beta\)-adrenergic receptors on the vascular smooth muscle).\(^7,9\)

Structural Responses to Metabolic Demand
In addition to the acute functional response to exercise, there are chronic vascular adaptations to regular exercise.\(^10,11\) Preclinical models indicate that regular exercise can increase microvascular density, which seems to be because of the activation of angiogenic mechanisms (described below).\(^12,13\) In addition, regular exercise can increase the diameter of conduit arteries, in part because of enhanced endothelium-dependent vasodilation and increased sensitivity of the vascular smooth muscle to vasodilatory factors.\(^14,15\) Furthermore, a positive remodeling of the conduit arteries because of structural changes in the vessel wall has been described.\(^16,17\) The positive remodeling is under the influence of arteriogenic mechanisms (described below).

Impaired Vascular Response and Tissue Ischemia
There are multiple mechanisms that impair the functional and structural responses of the vasculature to metabolic demands of the tissue. Cardiovascular risk factors, such as hyperlipidemia, diabetes mellitus, hypertension, and tobacco use, each impair endothelium-dependent vasodilation.\(^18,19\) Their effect is in part because of reduced generation and increased degradation of vascular nitric oxide.\(^20\) Notably, even in the absence of occlusive arterial disease, a functional impairment in endothelial vasodilator function may reduce exercise capacity. In hypercholesterolemic apolipoprotein E–deficient mice, limb blood flow during exercise is reduced, and exercise capacity (as judged by time on the treadmill) is reduced.\(^21\) Similarly, in the absence of PAD, exercise capacity is impaired in humans with cardiovascular risk factors.\(^22\) Treatment of risk factors (as with statins or converting enzyme inhibitors) can improve endothelium-dependent vasodilation and enhance exercise capacity.\(^23,24\)

Of course, in patients with PAD, the major cause of demand/supply mismatch is a structural, rather than a functional, abnormality in the vessel wall.\(^25\) Specifically, the primary problem is the hemodynamically significant atherosclerotic disease that impedes flow. Impaired vasoreactivity plays little
Angiogenesis

New capillaries (Figure).

Arteriogenesis

By contrast, arteriogenesis is a positive remodeling of pre-existing collateral channels in the limb.34 There is little to no flow through these narrow, high resistance channels in a normal individual. However, when major conduits become severely narrowed or occluded, more flow becomes directed through the collateral channels. Under the influence of vascular shear stress, the diameter of these channels increase. This positive remodeling seems to be because of endothelial factors, as well as infiltrating macrophages. The remodeling process is characterized by dynamic restructuring of the extracellular matrix with degradation and synthesis; vascular smooth muscle cell apoptosis as well as proliferation, which lead to an increased diameter and thickness of the vessel.36 Monocytes and macrophages play a major role in this remodeling process, as they are recruited sites of arteriogenesis and generate growth factors, metalloproteinases, chemokines, and nitric oxide that may contribute to arteriogenesis.38 Finally, it is possible that arteriogenesis may occur de novo in the absence of pre-existing collateral channels, but there is no evidence for such a phenomenon in humans.

Vasculogenesis

Finally, adult vasculogenesis differs from angiogenesis and arteriogenesis in that new blood vessels are formed at least in part by the action of endothelial progenitor cells (EPCs).37 EPCs are largely of hematopoietic lineage and are characterized by cell-surface antigen markers including CD34, CD133, and VEGF receptor-2.42–47 EPCs originate from the bone marrow and can circulate the blood and localize in regions of blood vessel formation and facilitate microvascular regeneration by paracrine or direct mechanisms.42–46 They are recruited by VEGF and stromal-derived factor 1 generated by the ischemic tissue. These circulating cells contribute to the expansion of the microvasculature via multiple mechanisms, with their secretion of paracrine factors playing a prominent role. In addition, a small subset of these cells seem to be of endothelial lineage potential. This subset of EPCs seem to incorporate into the vasculature of the ischemic region to contribute to the vascular response.48

The contribution of progenitor cells to new blood vessel formation has been the subject of controversy. The most definitive studies have used genetic markers, bone marrow replacement, and parabiosis models to document the existence of circulating cells that contribute to angiogenesis in the ischemic limb.37 With respect to negative studies, these may be
Angiogenesis is triggered by reduced oxygen delivery to the tissue, which induces the elaboration by ischemic cells of angiogenic factors such as vascular endothelial growth factor (VEGF). Angiogenesis is characterized by capillary sprouting, endothelial cell migration, proliferation, and lumino genesis to generate new capillaries. Adult vasculogenesis is mediated by the action of circulating cells such as endothelial progenitor cells (EPCs). EPCs are a heterogeneous population of cells, largely of hematopoietic lineage, and are characterized by cell-surface antigen markers including CD34, CD133, and VEGF receptor 2 (VEGFR-2). These circulating cells contribute to the expansion of the microvasculature via multiple mechanisms, secretion of paracrine factors playing a prominent role. A small subset of these cells seem to incorporate into the vasculature (inosculation). Arteriogenesis is a positive remodeling of pre-existing collateral channels in the limb. There is little to no flow through these narrow, high resistance channels in healthy individuals. However, when major conduits become severely narrowed or occluded, more flow becomes directed through the collateral channels. Under the influence of vascular shear stress, the diameter of these channels increase. This positive remodeling seems to be because of endothelial factors, as well as infiltrating macrophages. The remodeling process is characterized by dynamic restructuring of the extracellular matrix with degradation and synthesis; vascular smooth muscle cell apoptosis as well as proliferation, which lead to an increased diameter and thickness of the vessel.

related to the fidelity of the engineered markers. In any event, the fidelity of murine models to human physiology is well established to be variable at best. In this regard, there are data from human studies that provide clear evidence of the role of circulating cells in vascular repair. These data, generated by examining hearts from patients who had undergone sex-mismatched transplants, reveal that extracardiac cells contribute between 14% and 40% of the EC population in the donor heart, with evidence that the contribution was greatest in the microcirculation and precipitated by injury signals.

In animal models of PAD, there is strong evidence that multiple mechanisms contribute to the vascular response to acute and chronic ischemia. In PAD patients, these mechanisms are not as robust, or may not even be operative to any significant degree, as discussed below. Furthermore, there is great heterogeneity between patients in their vascular response to chronic ischemia. Most notably, clinicians are well aware that patients with the same degree of arterial occlusive disease in the named conduits may have dramatically different impairments in their functional capacity. For example, one patient with an occluded superficial femoral artery may be much less symptomatic than another, because of robust generation of geniculate collaterals. These collaterals connect branches of the deep femoral artery with those of the popliteal artery, thus providing a biological bypass around the occluded superficial femoral artery.

In patients with PAD, the number of EPCs is reduced. This may be because of an adverse effect of cardiovascular risk factors on their mobilization or self-renewal, as the risk factor burden is known to be inversely correlated to the numbers of these circulating cells. Furthermore, the function of these cells is impaired in PAD, as assessed by their ability to form colonies and to incorporate into pre-existing vascular networks ex vivo.

Trials of Angiogenic Therapies

Preclinical models of PAD have been developed to test angiogenic therapies. The murine hindlimb ischemia model is most commonly used. In this model, the superficial femoral artery is ligated proximally and distally, and the segment in between the ligatures is excised. The common femoral artery is also ligated, to obstruct flow to the deep femoral artery. Typically, Bl6 mice are used over the age of 12 weeks, as younger animals recover so quickly and completely that angiogenic agents cannot be easily tested. The angiogenic agents or vehicle are most frequently injected directly into the ischemic muscle of the limb. The effect on blood flow is followed noninvasively by laser Doppler spectroscopy, and angiogenic response can be quantified by microscopic examination of stained cross-sections of the tissue. In some studies, functional capacity is also assessed (e.g., by treadmill testing). In other studies, strains of mice are used that have greater sensitivity to ischemia. For example, the experimental procedure described above, when performed in the BalbC mouse, causes severe ischemia and extensive gangrene. This difference between strains in ischemic response has led to new insights regarding the determinants of critical limb ischemia (CLI) as discussed below. In addition, rabbits and swine are also used as models for PAD, but less frequently.

The preclinical studies provided proof-of-concept that exogenous administration of several cytokines could enhance angiogenesis, arteriogenesis, and adult vasculogenesis in ischemic limbs, improve limb blood flow, and reduce tissue loss. Promising preclinical studies with VEGF, fibroblast...
### Table 1. Selected Clinical Trials of Gene Therapy Products for Critical Limb Ischemia

<table>
<thead>
<tr>
<th>Reference (Trial)</th>
<th>Product</th>
<th>Dosage</th>
<th>Delivery Method</th>
<th>n</th>
<th>Rutherford Class</th>
<th>Follow-Up Duration</th>
<th>Outcomes: Bioactivity Parameters Improved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fibroblast growth factor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belch et al55 (TAMARIS)</td>
<td>FGF-1; plasmid</td>
<td>8×0.5 mg injections for 4 sessions</td>
<td>IM</td>
<td>525</td>
<td>Class 5–6</td>
<td>12 mo</td>
<td>No changes in major amputation or death rates</td>
</tr>
<tr>
<td>Comerota et al152</td>
<td>FGF-1; plasmid</td>
<td>Dose escalation; 1×500, 1×1000, 1×2000, 1×4000, 1×8000, 1×16000 mcg; or 2×500, 2×1000, 2×4000, 2×8000 mcg</td>
<td>IM</td>
<td>51</td>
<td>Class 4–6</td>
<td>6 mo</td>
<td>Decrease in pain, aggregate ulcer size; Increased TcPO2, ABI</td>
</tr>
<tr>
<td>Nikol et al153 (TALISMAN-201)</td>
<td>FGF-1; plasmid</td>
<td>8×0.5 mg injections for 4 sessions</td>
<td>IM</td>
<td>125</td>
<td>No option CLI</td>
<td>12 mo</td>
<td>Decreased amputation rate; no changes in ulcer healing</td>
</tr>
<tr>
<td>Lederman et al56 (TRAFFIC)</td>
<td>FGF-2; recombinant</td>
<td>30 mcg/kg single dose or 30 mcg/kg double dose (day 1+day 30)</td>
<td>IA</td>
<td>190</td>
<td>Class 2–3</td>
<td>3 mo</td>
<td>Increase peak walking time at 90 days; no change in quality of life or ABI</td>
</tr>
<tr>
<td><strong>Vascular endothelial growth factor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rajagopalan et al58 (RAVE)</td>
<td>VEG121; adenovirus</td>
<td>Low dose 4×10^6 pu; high dose 4×10^10 pu; 20 injections</td>
<td>IM</td>
<td>105</td>
<td>Class 1–3</td>
<td>6 mo</td>
<td>No changes in peak walking time or ABI; increased peripheral edema</td>
</tr>
<tr>
<td>Baumgartner et al154</td>
<td>VEGF165; plasmid</td>
<td>4000 mcg</td>
<td>IM</td>
<td>9</td>
<td>Class 4–6</td>
<td>10 wk</td>
<td>Increased vascularity on digital subtraction angiography (DSA); healing of ischemic ulcers; proliferation of endothelial cells on pathology</td>
</tr>
<tr>
<td>Makinen et al155</td>
<td>VEGF165; plasmid and adenovirus</td>
<td>2×10^10 pfu VEGF-Ad; or 2 mg/2mL VEGF plasmid</td>
<td>IA</td>
<td>56</td>
<td>Class 1–3</td>
<td>6 mo</td>
<td>Increased vascularity on DSA</td>
</tr>
<tr>
<td>Kusumanto et al156</td>
<td>VEGF165; plasmid</td>
<td>2 mg each for 2 session</td>
<td>IM</td>
<td>54</td>
<td>Class 4–6</td>
<td>100 days</td>
<td>No changes in amputation rates or rest pain; improvements in skin ulceration, ABIs, TBIs</td>
</tr>
<tr>
<td><strong>Hypoxia-inducible factor 1-alpha</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rajagopalan et al60</td>
<td>HIF-1alpha; adenovirus</td>
<td>Dose escalation; 1×10^8 to 2×10^11 viral particles</td>
<td>IM</td>
<td>34</td>
<td>No option CLI</td>
<td>12 mo</td>
<td>No serious adverse events attributable to study treatment; no amputations in 2 highest dose groups; complete rest pain resolution in 14 of 32 patients and complete ulcer healing in 5 of 18 patients</td>
</tr>
<tr>
<td>Creager et al61</td>
<td>HIF-1alpha; adenovirus</td>
<td>2×10^6; 2×10^8; 2×10^9 viral particles; or placebo</td>
<td>IM</td>
<td>289</td>
<td>Class 1–3</td>
<td>12 mo</td>
<td>No significant differences in peak walking time, claudication onset time, ABI, or quality of life</td>
</tr>
<tr>
<td><strong>Developmental endothelial locus-1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grossman et al157</td>
<td>Del-1; plasmid</td>
<td>42 mg plasmid or placebo over 21 injections in each leg (84 mg per subject)</td>
<td>IM</td>
<td>105</td>
<td>PAD and stable exercise-limiting IC</td>
<td>12 mo</td>
<td>Improvement in peak walking time, ABI, claudication onset time, and quality of life but no difference between control group</td>
</tr>
<tr>
<td><strong>Hepatocyte growth factor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morishita et al63</td>
<td>HGF; plasmid</td>
<td>Either 2 or 4 mg (4 or 8 injections)</td>
<td>IM</td>
<td>22</td>
<td>Fontaine Iib, III, or IV,</td>
<td>2 yr</td>
<td>ABI, pain relief, and ulcer healing were improved in the majority of patients</td>
</tr>
<tr>
<td>Powell et al158 (HGF-STAT)</td>
<td>HGF; plasmid</td>
<td>0.4 mg×8 for 3 sessions (low); 4 mg×8 for 2 sessions (mid); 4 mg×8 for 3 sessions (high)</td>
<td>IM</td>
<td>104</td>
<td>Class 4–6</td>
<td>12 mo</td>
<td>Increased TcPO2 at 6 mo in high-dose group; no changes in amputation, death, ulcer size, wound healing, ABI, TBI</td>
</tr>
<tr>
<td>Powell et al159 (HGF-0205)</td>
<td>HGF; plasmid</td>
<td>0.5 mg×8 for 3 sessions</td>
<td>IM</td>
<td>27</td>
<td>Class 5–6</td>
<td>6 mo</td>
<td>No change in wound healing or amputation; increase in TBI at 6 mo; increase rest pain improvement</td>
</tr>
<tr>
<td>Shigematsu et al160</td>
<td>HGF; plasmid</td>
<td>0.5 mg×8 for 2 sessions</td>
<td>IM</td>
<td>40</td>
<td>Class 4–5</td>
<td>3 mo</td>
<td>Increased reduction in ulcer size; increased quality of life; no change in rest pain or ABI</td>
</tr>
<tr>
<td>Henry et al161</td>
<td>HGF (VM202); plasmid</td>
<td>Dose escalation 2–16 mg</td>
<td>IM</td>
<td>12</td>
<td>No option CLI</td>
<td>12 mo</td>
<td>Increase in median ABI/TBI; decrease in pain (visual analog scale)</td>
</tr>
<tr>
<td>Gu et al162</td>
<td>HGF (VM202); plasmid</td>
<td>4 mg; 8 mg; 12 mg; 16 mg</td>
<td>IM</td>
<td>21</td>
<td>Class 4–6</td>
<td>3 mo</td>
<td>Increase in mean ABI and TcPO2; decrease in pain; improved wound healing</td>
</tr>
</tbody>
</table>

ABI indicates ankle brachial index; Del-1, developmental endothelial locus-1; CLI, critical limb ischemia; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; HIF-1α, hypoxia-inducible factor-1 alpha; IA, intra-arterial; IC, intermittent claudication; IM, intramuscular; PAD, peripheral artery disease; TBI, toe brachial index; TcPO2, transcutaneous oxygen pressure; and VEGF, vascular endothelial growth factor.
growth factor (FGF), hepatocyte growth factor (HGF), and HIF-1α led to clinical trials in PAD which are briefly described below (Table 1).

**Fibroblast Growth Factor**
The first randomized clinical trial of angiogenic therapy was with recombinant human basic FGF for the treatment of intermittent claudication (IC). In this study, basic FGF was administered weekly by intravenous infusions of 2 μg/kg for 6 sequential weeks (total dose 12 μg/kg)\(^{55}\). The primary efficacy end point was change in peak walking time on a graded exercise treadmill protocol. The study was stopped prematurely after treatment of the first 24 subjects because of clinically significant proteinuria in 5 of the 16 subjects who received systemic basic FGF. The small sample size limited evaluation of the predefined efficacy end points; however, there was no significant difference between the treatment and control groups for any of the measures of efficacy. The importance of this study is that it affirmed the view that systemic administration of angiogenic therapy should be limited in time and space to reduce the risk of side effects. Subsequent studies used infusions directly into limb arteries\(^ {56}\) or injections of the angiogenic agents into the limb musculature to reduce the risk of systemic side effects. In the TRAFFIC (Therapeutic Angiogenesis with FGF-2 for Intermittent Claudication) study, intra-arterial administration of recombinant FGF-2 increased peak walking time at 90 days. A repeat infusion at 30 days was no better than one infusion. The findings of TRAFFIC supported the concept of therapeutic angiogenesis as a potential treatment strategy for PAD, but the intra-arterial use of FGF-2 has not been pursued in phase III studies. A phase 1/2a study of FGF gene therapy delivered intramuscularly using a non-transmissible recombinant Sendai virus has been completed\(^ {57}\), and a phase 2a study is underway in patients with IC.

**Vascular Endothelial Growth Factor**
The Regional Angiogenesis with Vascular Endothelial growth factor (RA VE) study was a randomized clinical trial assessing the benefit of an adenoviral construct encoding VEGF121 (AdVEGF) in patients with primarily unilateral exercise-limiting IC\(^ {58}\). Study subjects were randomized to low-dose (4×10^9 particle units) or high-dose (4×10^10 particle units) administered as 20 intramuscular injections to the symptomatic leg in a single session. This study was not encouraging because the primary efficacy end point, change in peak walking time at 12 weeks, did not differ between the placebo, low-dose, or high-dose groups. The findings of TRAFFIC supported the concept of therapeutic angiogenesis as a potential treatment strategy for PAD, but the intra-arterial use of FGF-2 has not been pursued in phase III studies. A phase 1/2a study of FGF gene therapy delivered intramuscularly using a non-transmissible recombinant Sendai virus has been completed, and a phase 2a study is underway in patients with IC.

**Hypoxia-Inducible Factor-1α**
As described above, HIF-1α is a transcriptional factor that orchestrates the tissue response to hypoxia. The WALK

---

### Table 2. Randomized Controlled Trial Studies Studying Unselected BM-MNC or PB-MNC for Critical Limb Ischemia

<table>
<thead>
<tr>
<th>Reference (Trial)</th>
<th>Cell Type</th>
<th>Cell Dose</th>
<th>Delivery Method</th>
<th>Subject No.</th>
<th>Indication</th>
<th>Follow-Up</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow–derived mononuclear cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Tongeren et al(^ {98})</td>
<td>BM-MNC</td>
<td>10^9 cells (included 10^6 CD34+ cells)</td>
<td>IA+IM 15:IM 12:IA+IM</td>
<td>27</td>
<td>No option CLI</td>
<td>12 mo</td>
<td>Significant improvements for both tx arms in ABI, pain score, pain-free walking distance with cell therapy compared with baseline. No significant difference in limb salvage rates between tx arms</td>
</tr>
<tr>
<td>Walter et al(^ {143}) (PROVASA)</td>
<td>BM-MNC</td>
<td>10^9 cells (included 10^6 CD34+)</td>
<td>Dose escalation: single dose or double dose</td>
<td>IA</td>
<td>40</td>
<td>CLI RC 4–6</td>
<td>6 mo</td>
</tr>
<tr>
<td>Iafra et al(^ {144}) (BMAC)</td>
<td>BM-MNC</td>
<td>10^6 cells</td>
<td>IM</td>
<td>48</td>
<td>RC 4–5</td>
<td>3 mo</td>
<td>Improvement in amputation, pain, quality of life, Rutherford classification, and ABI compared with control</td>
</tr>
<tr>
<td>Benoit et al(^ {163}) (BMAC)</td>
<td>BM-MNC</td>
<td>10^7 cells</td>
<td>IM</td>
<td>48</td>
<td>RC 4–5</td>
<td>6 mo</td>
<td>Lower amputation rates compared with placebo</td>
</tr>
<tr>
<td>Prochazka et al(^ {169})</td>
<td>BM-MNC</td>
<td>Unspecified</td>
<td>IM</td>
<td>96</td>
<td>RC 4–6</td>
<td>4 mo</td>
<td>Significant improvements in limb salvage rates and ABI</td>
</tr>
<tr>
<td>Peripheral blood–derived mononuclear cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang et al(^ {150})</td>
<td>PB-MNC</td>
<td>10^9 (=0.4% CD34+) cells</td>
<td>IM</td>
<td>28</td>
<td>RC 4–6</td>
<td>3 mo</td>
<td>Significant improvements in ABI, ulcer healing, Laser Doppler blood perfusion, angiographic scores, limb salvage with cell therapy compared with randomized control</td>
</tr>
<tr>
<td>Ozturk et al(^ {154})</td>
<td>PB-MNC</td>
<td>10^7</td>
<td>IM</td>
<td>40</td>
<td>RC 4–6</td>
<td>3 mo</td>
<td>Improved ABIs, pain scores</td>
</tr>
<tr>
<td>Mohammadzadeh et al(^ {155})</td>
<td>PB-MNC</td>
<td>10^7</td>
<td>IM</td>
<td>21</td>
<td>CLI, DM</td>
<td>3 mo</td>
<td>Improved ABIs, amputation rates</td>
</tr>
</tbody>
</table>

ABI indicates ankle brachial index; BM-MNC, bone marrow–derived mononuclear cell; CLI, critical limb ischemia; DM, diabetes mellitus; IA, intra-arterial; IM, intramuscular; PB-MNC, peripheral blood–derived mononuclear cell; and RC, Rutherford classification.
study tested the efficacy of an adenoviral construct encoding a constitutively active form of HIF-1α in patients with IC. Previously, a small pilot study in patients with CLI suggested that the gene therapy was well-tolerated. In a subsequent randomized clinical trial involving over 400 claudicants, patients received 20 injections of the construct into each limb, at one study visit. The primary end point was the change in treadmill exercise time at 6 months by comparison to baseline (before the injections). Regrettably, this well-conducted large randomized clinical trial was negative because there was no difference between the active and placebo groups, which each improved ≈25% in maximal treadmill time.

**Developmental Endothelial Locus-1**

The angiomatrix protein developmental endothelial locus-1 induces a potent angiogenic response, through coordinate upregulation of the integrins ανβ5 and ανβ3. The therapeutic potential of this angiogenic protein was tested using a plasmid-expressing developmental endothelial locus-1. One hundred subjects with bilateral IC were randomized to bilateral intramuscular delivery of the plasmid or placebo. The study drug was administered at one visit, being delivered as 42 intramuscular injections in both lower extremities. Four weeks after the initial injection, the dose was repeated, giving study subjects a total of 4 or 8 mg of HGF plasmid. The 2 month follow-up of these individuals revealed that surrogate markers [ankle-brachial index (ABI); pain relief; ulcer healing] were improved in the majority of

**Table 3. Randomized Controlled Trials Comparing Cell Types for Critical Limb Ischemia**

<table>
<thead>
<tr>
<th>Reference (Trial)</th>
<th>Cell Types</th>
<th>Cell Dose</th>
<th>Delivery Method</th>
<th>Subject No.</th>
<th>Indication</th>
<th>Follow-Up</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tateishi-Yuyama et al51 (TACT trial)</td>
<td>BM- vs PB-MNCs</td>
<td>10^8 BM- or PB-MNCs (the BM-MNC infusion included 10^8 CD34+ cells)</td>
<td>IM gastroc</td>
<td>45</td>
<td>RC 4–6</td>
<td>24 wk</td>
<td>Significant improvements in ABI, TcPO2, rest pain, pain-free walking time with BM-MNC compared with placebo (pilot study), as well as with BM-MNC compared with PB-MNC (randomized control trial)</td>
</tr>
<tr>
<td>Matoba et al52 (TACT trial)</td>
<td>BM- vs PB-MNCs</td>
<td>10^8 BM-MNC vs PB-MNC's as control (the BM-MNC infusion included 10^8 CD34+ cells)</td>
<td>IM</td>
<td>115</td>
<td>RC 4–6, 74 AS0</td>
<td>41 TAO</td>
<td>Significant improvements in leg pain, walking distance, ulcer size at 2 yrs with BM-MNC compared with PB-MNC. No significant difference in ABI or TcPO2 detected</td>
</tr>
<tr>
<td>Huang et al53</td>
<td>BM- vs PB-MNCs</td>
<td>10^8 G-CSF–mobilized PB-MNC (includes 10^8 CD34+ cells) vs 10^8 BM-MNC (includes 10^8 CD34+ cells)</td>
<td>IM</td>
<td>150</td>
<td>Any RC; AS0</td>
<td>3 mo</td>
<td>Significant improvements in ABI, skin temperature, rest pain with PB-MNC compared with BM-MNC. No significant difference in TcPO2, pain-free walking distance or amputation rates detected</td>
</tr>
<tr>
<td>Kamata et al54</td>
<td>BM- vs PB-MNCs</td>
<td>10^8 BM-MNC or PB-MNC (includes 10^8 CD34+ cells in each group) Note: PB-MNC were not mobilized</td>
<td>IM</td>
<td>6</td>
<td>RC 4–6 Vasculitic</td>
<td>1 mo</td>
<td>Significant improvements in rest pain (both treatment groups) with both BM-MNC and PB-MNC therapy</td>
</tr>
<tr>
<td>Lu et al55</td>
<td>BM-MSC vs BM-MNC</td>
<td>Unspecified</td>
<td>IM</td>
<td>41</td>
<td>CLI, DM, RC 5–6</td>
<td>6 mo</td>
<td>BM-MNC and BM-MSC associated with improved ABIs, TcO2, and pain-free walking time. Collateral score, faster ulcer healing with BM-MSC&gt;BM-MNC&gt;placebo</td>
</tr>
</tbody>
</table>

ABI indicates ankle brachial index; ASO, arteriosclerosis obliterans; BM-MNC, bone marrow derived mononuclear cell; BM-MSC, bone marrow derived mesenchymal stem cell; CLI, critical limb ischemia; DM, diabetes mellitus; IA, intra-arterial; IM, intramuscular; PB-MNC, peripheral blood derived mononuclear cell; RC, Rutherford classification; TAO, thromboangiitis obliterans; and TcPO2, transcutaneous oxygen pressure.
patients. No significant side effects of the gene therapy were reported at 6 months. At 2-year follow-up, the improvements were largely maintained.64 A global phase III study is now underway to study the efficacy of intramuscular injection of this therapy in patients with CLI.

**Summary of Angiogenic Therapies for PAD**

Despite substantial evidence of efficacy in preclinical studies, as well as some promising phase I/IIa human trials, larger randomized clinical trials of angiogenic therapies for ICor CLI have been negative. The discordance between the early developmental studies and the larger randomized clinical trials may be because of problems with the animal model. Most of the proof-of-concept preclinical studies have been in murine models of hindlimb ischemia. Typically, this model is a surgically induced ischemia in the absence of any cardiovascular risk factors, other than age (most often older C57 Bl6J mice are used because younger mice of this strain rapidly recover hindlimb blood flow to normal levels, as a result of the generation of collateral vessels and robust endogenous angiogenesis). Obviously, the typical murine model is different from PAD patient that are entered into clinical trials. The addition of cardiovascular risk factors to murine models may improve their predictive value. For example, diabetes mellitus is common in patients with PAD and is known to impair angiogenesis. Diabetes mellitus disrupts many processes required for angiogenesis, such as the elaboration of nitric oxide, VEGF, and microRNA-regulating angiogenic processes.65 Thus, in murine models of hindlimb ischemia, typical murine model is different from PAD patient that are entered into clinical trials. The addition of cardiovascular risk factors to murine models may improve their predictive value. For example, diabetes mellitus is common in patients with PAD and is known to impair angiogenesis. Diabetes mellitus disrupts many processes required for angiogenesis, such as the elaboration of nitric oxide, VEGF, and microRNA-regulating angiogenic processes.65 Thus, in the absence of clinically relevant risk factors and disease, any benefit of an angiogenic agent in a mouse model may not be informative in humans. Murine models of hindlimb ischemia which incorporate cardiovascular risk factors, and vascular obstruction because of atherosclerosis, might provide more predictive results for potential angiogenic therapies in PAD.

It is also important to consider the strain differences in the response to ischemia. In response to the surgical induction of hindlimb ischemia, the C57Bl6 mice have a perfusion defect (the severity increasing with the age of the mouse) but rarely any tissue loss. By contrast, the BalbC strain manifests a profound ischemia, with gangrene and limb necrosis, after the same experimental procedure.66 The vulnerability of this strain has been traced to a genetic difference in a quantitative trait locus on chromosome 7 harboring 37 genes.67 The genetic difference in this strain may mediate reduced angiogenesis and collateral formation and increased sensitivity of the skeletal muscle to ischemia.68 Notably, the BalbC mice express lower levels of microRNA 93 in their ischemic skeletal muscle.69 This microRNA regulates multiple genes that modulate cell proliferation and apoptosis and may play a critical role in perfusion recovery from hindlimb ischemia. An understanding of the genetics of ischemic response is likely to yield novel insights that may provide new therapeutic directions.

Furthermore, there is insufficient knowledge regarding the methods for administration of the angiogenic therapy. For any angiogenic agent, there are many unknowns regarding the dose, the frequency of administration, and method of delivery in patients with PAD. Should angiogenic therapy be administered to the parenchyma of the tissue (ie, the ischemic skeletal muscle) so as to enhance angiogenesis within the tissue? Or should the therapy be targeted to the vicinity of the named conduits and to the proximity of known routes for collateral vessels? For example, the geniculate collaterals are supplied by branches of the deep femoral artery and these collaterals reconstitute the popliteal artery in the setting of superficial femoral artery occlusion. Could angiogenic/arteriogenic therapy targeted to these vessels enhance perfusion by increasing collateral flow?

With respect to the trials of angiogenic/arteriogenic therapies for CLI, the great majority of past trials were not informed by the recent concept of angiosomes. Angiosomes comprise a segment of tissue composed of the skin, subcutaneous tissue, muscle, and bone perfused by a specific artery and drained by a specific vein.70 In the foot, there are 6 angiosomes: 3 of these are supplied by the posterior tibial artery, 2 by the peroneal artery (n=2), and one by the anterior tibial artery. A recent retrospective review suggests that revascularization efforts (surgical or endovascular) are more likely to be successful

---

**Table 4. Randomized Controlled Trials Studying Marker-Selected Cells for Critical Limb Ischemia**

<table>
<thead>
<tr>
<th>Reference (Trial)</th>
<th>Cell Type(s)</th>
<th>Cell Dose</th>
<th>Delivery Method</th>
<th>Subject No.</th>
<th>Indication</th>
<th>Follow-Up</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Losordo et al115</td>
<td>PB-CD34+</td>
<td>Dose escalation: Placebo, 10^6 (n=7), 10^9 (n=9)</td>
<td>IM</td>
<td>28</td>
<td>RC 4-5</td>
<td>12 mo</td>
<td>Nonsignificant improvement in amputation rates at 12 mo (P=0.058) with increased dose cell therapy compared with placebo-control</td>
</tr>
<tr>
<td>Perin et al122</td>
<td>ALDH^+ cells (CD34+, 133+, 14+,117+) vs BM-MNC</td>
<td>Unspecified</td>
<td>IM</td>
<td>21</td>
<td>RC 4-5</td>
<td>6 mo</td>
<td>Dose-related nonsignificant trend with reduced amputation rate</td>
</tr>
<tr>
<td>Powell et al117</td>
<td>TRC (CD90+, 14+, 45+, 105+/14+/45+ cells)</td>
<td>10^6-10^7</td>
<td>IM</td>
<td>86</td>
<td>RC 4-6</td>
<td>12 mo</td>
<td>Decreased treatment failure at 12 mo (major amputation of the injected leg, all-cause mortality, doubling of total wound surface area from baseline, or de novo gangrene)</td>
</tr>
<tr>
<td>Kirana et al118</td>
<td>TRC, BM-MNC</td>
<td>10^7 TRC 10^8 BM-MNC</td>
<td>IM/IA</td>
<td>24</td>
<td>RC 4-6</td>
<td>12 mo</td>
<td>No difference between cell therapies</td>
</tr>
</tbody>
</table>

ALDH^+ cells indicates aldehyde dehydrogenase (bright) cells; BM-MNC, bone marrow–derived mononuclear cell; IA, intra-arterial; IM, intramuscular; PB-MNC, peripheral blood–derived mononuclear cell; RC, Rutherford classification; and TRC, tissue repair cells.
when targeted to the vessel supplying the affected angiosome in the foot. Future trials of angiogenic/arteriogenic therapies for CLI will likely incorporate this concept.

In this regard, in the development of new PAD therapies, more attention should be paid to therapeutic arteriogenesis. Whereas the microvascular phenomenon of angiogenesis may be sufficient to improve perfusion to the small tissue volume of the ischemic murine hindlimb, the metabolic activity and much larger volume of the human leg require larger conduits that provide adequate inflow. The growth factor granulocyte macrophage-colony stimulating factor (GM-CSF) is known to increase circulating monocytes and has been tested in clinical trials. Regrettably, in the largest study in patients with IC, multiple subcutaneous administrations of GM-CSF over 14 days did not improve walking distance and ABIs. Furthermore, GM-CSF therapy may increase the risk of acute coronary events. Clearly, new insights into the mechanisms of arteriogenesis are needed so as to develop effective methods to therapeutically manipulate arteriogenesis. Some basic research insights from preclinical studies that may be present therapeutic targets include endothelial-derived syneclin as well as the DII4-Notch signaling pathway.

Trials of Cell-Based Therapies

Asahara’s discovery of the EPC subpopulation in 1997 marked the dawn of cell therapy as a therapeutic approach to vascular disease. Evidence suggested that these cells are derived from the bone marrow and are recruited into the circulating blood where they home to sites of ischemia. Since then, preclinical studies have made a compelling case for pursuing the use of these and other progenitor cells in trials for cardiovascular regeneration. In general, preclinical studies support the notion that a fraction of bone marrow–derived mononuclear cells (BM-MNCs) support angiogenesis and vasculogenesis.

Parenthetically, the widely used term EPC is now embedded into the vernacular of vascular biology; however, it is recognized that the term is shorthand for a much more complex biology. The surface markers that are commonly used for identification of human EPCs include markers that are not specific for endothelial lineage, such as CD133 and kinase insert domain receptor. In addition, methods for harvesting, purifying, and culturing EPCs are not standardized. Thus, semantic confusion is compounded by methodological variation. Within this population of cells, there are true endothelial progenitors that can incorporate into the vascular network, whereas hematopoietic progenitors may contribute by secreting angiogenic cytokines. In cell culture, EPCs may form early-outgrowth and late-outgrowth colonies. Cells derived from the former colonies are clearly not of endothelial origin, expressing markers of hematopoietic lineage, and are morphologically distinct from late-outgrowth cells, which grow in a cobblestone pattern reminiscent of ECs. At present, there are no surface markers that clearly distinguish early endothelial progenitors; the best approach currently is to define endothelial lineage functionally (ie, by the ability of true EPCs to enucleate into a new or pre-existing vascular network).

In addition, mature ECs might be recruited into the circulation, and home to sites of ischemia, so as to increase capillary density. In a parabiotic model, hindlimb ischemia led to the incorporation of circulating c-kitCD45 progenitors in the microvasculature of the ischemic limb. Bone marrow replacement studies revealed that about half of these cells were derived from the bone marrow and about half were not. The authors proposed that these cells were ECs that were recruited into the blood, and circulated to the site of hindlimb ischemia, presumably under the influence of homing signals such as stromal-derived factor 1.

To date, over 50 clinical studies have been reported on the treatment of peripheral artery disease with progenitor cells. Studies have included patients of varying PAD severity, including those with IC to those CLI. Select past and ongoing studies include those with less severe ischemia (ie, patients with IC, Rutherford class 1–3). However, the majority of clinical trials of cell therapy for PAD have primarily focused on CLI patients (Rutherford class 4–6) in small phase I or II studies. Since the first pilot clinical study to evaluate treatment of peripheral vascular disease with stem cell therapy in 2002, therapeutic details such as patient selection, effective cell type selection and processing, optimal dosage, and delivery route continue to be characterized.

A variety of cell types have been studied as potential PAD treatments, including unselected BM-MNC or peripheral blood MNC (PB-MNC), marker-specific cells selected from the marrow or blood, mesenchymal stem cells (MSCs), and adipose tissue–derived regenerative cells. Discussed below are the clinical studies investigating cell therapies for peripheral vascular disease treatment.

Bone Marrow–Derived Mononuclear Cells (Tables 2 and 3)

Mononuclear cells, harvested from either bone marrow or blood, are comprised of a heterogeneous mix of blood cells, nonhematopoietic stromal cells such as MSCs and EPCs, and these cells secrete a variety of proangiogenic cytokines. The first report of an autologous stem cell therapy for the treatment of ischemic limbs was through the TACT (Therapeutic Angiogenesis using Cell Transplantation) study using unselected MNCs from both the bone marrow (BM-MNC) and peripheral blood (PB-MNC) for the treatment of CLI. The study reported improved rest pain, transcutaneous oxygen pressure (TcPO2), ABI, and pain-free walking distance by comparison to the control group (saline injection) at 6 months. Subsequent studies have investigated the safety and feasibility of autologous unselected BM-MNCs in ischemic limb treatment, primarily in small case series. Initial findings suggested clinical benefits of intramuscularly administered unselected BM-MNCs for ischemic limb treatment, including improved ABI, pain-free walking distance/time, wound healing, limb salvage, and Rutherford class. Recent studies have provided additional supportive evidence in randomized, controlled trials. These studies of BM-MNC administered intramuscularly to patients with severe limb ischemia report clinical improvement including lower amputation rates and improved ABI when compared with control treated subjects. While promising, these studies are not definitive.

Peripheral Blood–Derived Mononuclear Cell (Tables 2 and 3)

MNCs harvested from peripheral blood have also been actively examined in autologous cell therapy for ischemic limb
treatment. PB-MNCs are mobilized through granulocyte-colony stimulating factor injection, and cell collection from blood rather than bone marrow harvesting offers faster hematologic recovery and eliminates anesthetic medication use and anemia risk. Collective clinical findings of small case series show significant improvements in ABI, pain scale, walking distance, and limb salvage compared with baseline. Randomized trials of PB-MNCs have confirmed these early clinical improvements (3 months) in ABI and pain, although amputation rates did not differ between those treated with unselected PB-MNC versus the control group. One study reported significantly fewer patients facing major amputation of a limb in the group infused with PB-MNC versus those in the control group at the conclusion of the studied.

**BM-MNC Versus PB-MNC**

To date, 4 randomized controlled trials have directly compared BM-MNC with PB-MNC. The first study, by Tateishi-Yuyama et al, used CLI patients with bilateral ischemia as their own controls to directly compare the therapeutic effects of BM-MNC and PB-MNC in CLI patients out to 1 year. They showed that BM-MNC infusion resulted in significant improvements in ABI, TcPO2, rest pain, pain-free walking time compared with both the placebo group, and with those infused with PB-MNC. Notably, the dose of cells administered to the BM-MNC group was substantially lower, providing evidence that a cell dose threshold must be reached to achieve bioactivity. Subsequent comparative studies of similar sample size have reported inconsistent clinical outcomes. Although Huang et al reported that at 3 months, those treated with PB-MNC showed improved ABI and rest pain compared with patients receiving BM-MNC, Matoba et al, reporting on long-term follow-up of the TACT study, reported significant improvements in pain, walking distance, and ulcer size at 2 years in those infused with BM-MNC compared with those treated with PB-BMC, perhaps reflecting the same influence of dose as seen in the initial publication. One small open-label study reported that CLI vasculitis patients significantly improved in rest pain at 1 month with either BM-MNC or PB-MNC treatment.

**MNC Delivery Through Intramuscularly/Intra-arterially**

In addition to identifying suitable cell sources for PAD treatment, the influence of the administration route also needs to be defined. Although the studies described above have primarily evaluated the therapeutic effects of intramuscular administration of MNCs from either bone marrow or blood, the potential of intra-arterial MNC delivery is also being explored. Intramuscular delivery is hypothesized to result in a transient cell depot directly within the ischemic tissue site to allow both local paracrine activity as well as incorporation of cells into the neovascularature. Intra-arterial delivery is thought to direct stem cells into viable peri-ischemic zones with sufficient oxygen and nutrient content for cell function support. Intra-arterially delivered BM-MNC to ischemic limbs have been shown to result in increased capillary densities and improved ABI and pain-free walking distance at 1 year. The PROVASA (Intraarterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells for Induction of Neovascularization in Patients With Peripheral Arterial Occlusive Disease Study) study represents the only multicenter, randomized, controlled trial investigating intra-arterial BM-MNC therapy in CLI patients to date. The PROVASA study demonstrated dose-dependent ulcer healing improvement and rest pain reduction in those treated with intra-arterially administered BM-MNC compared with the placebo group. However, ABI or limb salvage rates did not differ between the groups. To date, only Lenk et al have studied the effects of intra-arterially administered PB-MNC on patients with end-stage PAD, in which those treated with unselected PB-MNC significantly improved in ABI and TcPO2, from baseline to 3 months.

Several smaller studies have reported on the clinical outcomes of concurrently delivering BM-MNC via intramuscularly and intra-arterially, and, collectively, these studies provide evidence of the early and late clinical gains including ABI, ulcer healing, pain-free walking distance, and limb salvage. In a randomized study of 27 no-option CLI patients, Van Tongeren et al showed a nonsignificant trend toward lower amputation rates in the intramuscular+intra-arterial group compared with the intramuscular group. Hence, larger studies are needed to clarify further the optimal route of therapeutic cell delivery. The JUVENTAS (Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia) study has reported on the clinical design of evaluating 110 to 160 CLI patients treated with intra-arterially administered BM-MNC, but outcomes of the study have yet to be reported.

**Marker-Selected MNCs (Table 4)**

There is still debate regarding the definition of the EPC. Not in question is the reality that the ECs that line the blood vessels and compose the capillaries at birth do not survive for 100 years. Similarly, the monthly growth of a vascular endometrium for ≥30 years seems to be by a means other than existing blood vessels. It seems that only a small subset of EPCs is of true endothelial lineage in humans. These endothelial colony-forming cells can form vascular structures in vivo but are rare, only 1 to 2 per 100 million BMC. Another subset of EPCs, which are more common, is of hematopoietic lineage. These EPCs share the same surface markers (CD31, CD105, CD144, CD146, von Willebrand factor, kinase insert domain receptor, and ulex europaeus agglutinin 1 lectin) and incorporate acetylated low-density lipoprotein, but they express the myeloid surface markers CD45 and CD14 and have other features of the monocyte/macrophage phenotype. Some of these cells may contribute to angiogenesis not by incorporating into the vasculature but by secreting angiogenic cytokines and matrix metalloproteinases. Still other bone marrow–derived cells can form pericytes, which associate with and stabilize endothelial networks.

EPCs are a populous of MNC, which can be isolated based on surface markers such as the progenitor marker CD34. Evidence suggests that a percentage of CD34 cells can differentiate into mature ECs and that CD34 cells in general facilitate vascular repair in various ischemic tissues. Preclinical studies of isolated human EPC transplantation in ischemic hindlimb in mice have demonstrated increased perfusion and higher limb salvage rate. Clinical safety and feasibility of CD34+ cells for ischemic limb treatment have been evaluated in a dose escalation trial of granulocyte-colony...
stimulating factor–mobilized peripheral blood CD34+ cells (3 doses: 10^5, 5×10^5, 10^6) administered by intramuscular injection.114 Any dose of CD34+ administered resulted in a total efficacy score improvement at 3 months, exhibited by pain and ulcer size reduction, and increases in toe brachial pressure index, TcPO2, and pain-free walking distance. Longer term clinical benefits were also reported in a 28-patient, randomized, double-blinded, controlled, dose-escalation study in which granulocyte-colony stimulating factor–mobilized selected CD34+ cells were administered by intramuscularly (ACT-34 CLI [Autologous Cell Therapy-34 Critical Limb Ischemia] trial).115 The study showed that at 12 months, amputation incidence was lower in the combined cell-treated groups (doses of 10^5 or 10^6 cells per kg body weight) compared with the control group (P=0.054). Additionally, each dose group trended toward improved amputation-free survival at 6 and 12 months. A mix of multiple cell lineages for PAD treatment have also been studied. Ixmyelocel-T or tissue repair cells consists of CD90+ cells [primarily of mesenchymal stem and progenitor cells and CD45+ cells (endothelial stem and progenitor cells)] harvested from the bone marrow and expanded in culture. In a randomized phase 2 trial (RESTORE-CLI [Use of Tissue Repair Cells (TRCs-Autologous Bone Marrow Cells) in Patients with Peripheral Arterial Disease to Treat Critical Limb Ischemia]), tissue repair cell administered intramuscularly to CLI patients resulted in a significantly prolonged time to treatment failure and trend toward increased amputation-free survival at 1 year.116,117 A randomized trial comparing tissue repair cells with unselected BM-MNCs (REVIVE-CLI [An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia]) was, unfortunately, recently terminated because of slow enrollment and a change in strategic focus of the sponsor. In a small randomized trial, Kirana et al118 reported nonsignificant trends toward improved ABI, TcPO2, and wound healing in patients treated with BMC or tissue repair cell, but no differences between the 2 groups were observed.

Another heterogeneous mix of MNC derived proangiogenic cell populations has been explored using high aldehyde dehydrogenase (ALDH) activity. ALDH is an oxidizing enzyme highly expressed in both embryonic and adult stem cells, and BM-MNCs selected for high ALDH activity express CD34+, CD133+, CD14+, and CD117+.119,120 Preclinically, treatment of mice ischemic hind limbs with BM-MNCs for high ALDH activity led to perfusion recovery and increased blood vessel density.121 A phase 1, randomized, controlled trial compared unselected BM-MNCs to BM-MNCs selected for high ALDH in the treatment of CLI, demonstrated significant ABI improvement in both groups. However, no differences were observed between the 2 groups, and neither treated group showed significant improvement in ischemic ulcer grade or TcPO2 compared with the control group.122 An ongoing study of ALDH bright cells is being conducted by the National Institutes of Health–sponsored Cardiovascular Cell Therapy Research Network.123

**Mesenchymal Stem Cells**

Mesenchymal stem cells have been pursued as a potential candidate for PAD cell therapy because of their multi-potent, paracrine, transdifferentiation, and immunosuppressive effects.124 Preclinical findings showed that bone marrow–derived mesenchymal stem cells (BM-MSCs) injected into ischemic hind limbs of rats led to greater perfusion and capillary density increase than BM-MNC administration. A randomized controlled trial comparing BM-MSCs to BM-MNCs was conducted on 41 CLI patients with diabetes mellitus and demonstrated significantly improved pain-free walking time in both groups at 6 months.125 Additionally, the BM-MSC infusion led to significantly greater collateral blood vessel scores than BM-MNC injection. All patients in the cell therapy group experienced ulcer healing, but those injected with BM-MSCs healed by 8 weeks while those receiving BM-MNCs showed healing by 12 weeks. These findings may suggest that BM-MSCs may offer faster wound healing compared with unselected BM-MNCs.

**Other Cell Types for PAD Therapy**

A combinatorial approach of infusing multiple cell types in ischemic areas has also been studied. A small phase I investigation of 10 patients with severe limb ischemia examined the effects of concurrently delivering BM-MNC (30×10^6) and BM-MSC (30×10^6) administered intramuscularly. Patients receiving the combination cell therapy reported significant ABI improvement as early as 1 month, which lasted out to the last follow-up at 10 months. Trends toward improved walking time, TcPO2, and quality of life were also observed.

Allogeneic MSCs have also been explored for PAD treatment, in an attempt to leverage their immune-modulating capabilities. In a phase I study of 20 CLI patients, intramuscular administration of allogeneic BM-MSC treatment led to a significantly increased ABI compared with the placebo group at 6 months.126

In addition to allogeneic MSCs, various cell types such as adipose-derived regenerative cells, induced pluripotent stem cells, and nuclear reprogrammed stem cells are currently being explored for proangiogenic potential for PAD treatment in preclinical models. Clinical studies using these cell sources are now required to determine whether these cell sources provide advantages compared with prior cell types.127-131

**Summary of Cell Therapies for PAD**

Since the publication of the TACT study, there have been >50 reported therapeutic cell trials in patients with PAD. Two thirds of these studies have been in patients with CLI as defined by rest pain or tissue necrosis, and the other 1/3 in patients with symptomatic PAD (ie, IC). Most of the trials have used BM-MNCs, with fewer using granulocyte-colony stimulating factor–mobilized PB-MNCs and fewer still using a specific cell type. Most of the trials have used intramuscular administration to the calf and thigh (10–80 sites) using a total of 1-10×10^7 CD34+ cells, although the dose of CD34 cells is only rarely prespecified. End points have included ankle-brachial pressure index, transcutaneous oxygen level, Laser Doppler perfusion, pain-free or maximal walking distance, relief of rest pain, or healing of ischemic ulcers.

Using these end points, modest signals of efficacy has been reported in most trials, but the confidence intervals are large. Most trials enrolled relatively small numbers of patients, followed for 1 or 2 years. Furthermore, in most trials, the characterization of the therapeutic cells and the evaluation of dose...
have both been limited. Often, there is no functional assessment of the cells. Together, these 3 phenomena, ie, lack of information about the drug, its dose or its potency, are challenges to the interpretation of the studies, and opportunities for future development, which appears warranted based on early signals of bioactivity.

As noted above, whether there is persistence of these cells in the ischemic tissues is controversial, with human and animal evidence of incorporation of progenitor cells in the vasculature, while other studies have failed to document these findings. Moreover, the mechanism(s) of their therapeutic effect (if any) remains to be fully understood. Preclinical animal studies suggest that progenitor cells can integrate into the ischemic tissue neovasculature and can secrete paracrine factors to increase the density and perfusion of the microvasculature. In addition, these transplanted progenitor cells secrete exosomes containing proteins, RNAs, and microRNAs that stimulate both receptor-mediated and genetic mechanisms and contribute to a significant component of the paracrine effect of progenitor cell transplantation. As a result, almost 10 years later, we do not know for certain if cell therapy in PAD is useful, or do we understand the mechanism of any clinical benefit. Furthermore, in the case of autologous adult stem cells, the conditions that give rise to PAD (eg, diabetes mellitus and tobacco exposure) may also decrease the number and function of the therapeutic cells. Despite this theoretical limitation, early clinical studies have provided evidence for safety and bioactivity/benefit. Augmenting the potency of autologous progenitors represents one potential means of overcoming the possible detriment conferred by the existence of comorbid conditions. Alternatively, allogeneic progenitor cells (such as mesenchymal stromal cells derived from adipose or placental tissue) may represent another possible approach, although these cells will encounter difficulties because of shortened tissue residence time, which may limit their effect. Although these allogeneic cells are easier to procure and amenable to tissue banking, there is little clinical or preclinical evidence of their efficacy. Nevertheless, the potential limitations of adult stem/progenitor cells provide a rationale for deriving and testing therapeutic cells from other sources.

The typical approach to isolate BM-MNCs or PB-MNCs for PAD cell therapy trials generates a heterogeneous population of cells that have not been completely characterized. It is possible that a greater effect size and more persistent benefit of cell therapy could be realized with a more precisely defined cell population. Although the use of multiple surface markers to isolate subpopulations of therapeutic cells is attractive scientifically, the use of a single surface marker for cell selection is a practical concession in terms of technical and cost factors. If multiple marker–selected cells are shown to have significant benefit compared with single maker cells, these technical challenges will have to be overcome.

Greater clarity is needed regarding the composition and fate of the cells that are used for cardiovascular cell therapy. Cells aspirated or mobilized from the bone marrow are a heterogeneous population of cells that may promote EC survival and proliferation, contribute to network formation, stabilize newly formed vessels, enhance myocardial cell survival, and incorporate into ischemic tissue. Improved characterization of the administered cells and dose–response relationships could provide insights into which cell types might be associated with these physiological processes, and with improvements in clinical endpoints. Greater knowledge about the therapeutic subset of cells could also provide guidance about the dose and frequency of administration required for optimum effects. The therapeutic product needs much better definition, so as to allow improved quality control, and monitoring of variation because of methodological or patient differences. New methodologies to comprehensively characterize cell therapies such as single cell mass cytometry might be used to comprehensively characterize the cell product. Quantification of these cellular subsets and their response to hypoxia may be more predictive of clinical responses. In addition, the study of cryopreserved cells is needed to permit multiple dosing which, logically, should any augment clinical benefits induced by a single administration. There is a long successful track record of the use of cryopreserved cells for hematopoietic cell transplant, and this history should provide guidance for the field of cardiovascular cell therapy.

It is also necessary to apply contemporary imaging methodologies to gain more insight into the distribution and fate of the injected cells and their effect on limb perfusion and anatomy. For example, molecular imaging using cells that are genetically modified (eg, with constructs encoding thymidine kinase) for positron emission tomography have been developed and are now in clinical trials for Food and Drug Administration approval. New developments in MRI, such as dynamic contrast-enhanced imaging, combined with innovative 4-dimensional algorithms, may provide greater precision of limb perfusion measurements to improve the ability to detect changes related to angiogenesis and arteriogenesis induced by therapeutic cell therapy. It is important to note that the regional differences in limb ischemia are dependent on the variability of the arterial anatomy and heterogeneity of the disease from one patient to the next. It is conceivable that the benefit of cell delivery might be enhanced by directing the cell injections to ischemic regions of the calf and thigh, as mapped by magnetic resonance perfusion imaging. One of the major challenges to developing therapies for CLI has been the lack of a reliable surrogate that is predictive of clinical success (ie, wound healing, pain relief, and avoidance of amputation). The development of a method of quantifying perfusion in the limb could, therefore, represent a breakthrough in the field.

**Beyond Adult Stem Cell Therapies**

In the case of PAD, there are preclinical data, and small clinical trials with adult progenitor cells, indicating that benefit may be achieved simply by injecting therapeutic cells into the ischemic muscle. However, to restore maximal levels of perfusion, it is likely that large diameter, low resistance conduits will be necessary. It is unlikely that injections of cells could create this benefit. An additional approach would be to provide the cell therapy as a biological conduit, incorporated into a cylindrical bioengineered matrix or decellularized cadaveric vessels. These bioengineered conduits would serve to replace autologous saphenous vein in patients that have insufficient or diseased veins.

An alternative approach would be to use vascular cells derived from embryonic stem cells or induced pluripotent stem cells. The generation of these cells and their differentiation into vascular cells have been previously reviewed. In brief,
both embryonic stem cell–derived or induced pluripotent stem cell–derived ECs, when injected into the ischemic hindlimb, can enhance capillary density and improve blood flow in preclinical models. These effects seem to be because of paracrine substances released by the cells, rather than their direct incorporation into the microvasculature of the ischemic limb. Whereas these studies are promising, the complex nature of stem cells and their derivatives presents several challenges. The use of human embryonic stem cells is confounded by ethical issues as well as the immune barrier. Whereas autologous induced pluripotent stem cell–derived cells avoid these issues, there remains concern about the possibility for teratoma formation. Cell populations derived from different sources or donors may not have the same safety and activity profiles, despite the use of the same processing methods on each population. Moreover, alterations to cell processing methods may lead to unintended changes in the safety and activity profile. The cells may also undergo genetic or epigenetic changes during cell culture, during isolation, expansion, or in cold storage. These factors are some of the liabilities when attempting to generate any stable, renewable, and consistent cell product.

Accordingly, another exciting approach is to use small molecules or growth factors to modify resident stem cells, or somatic cells, in a therapeutic manner. In this way, it may be possible to avoid the vagaries of therapy with exogenous cells. Proof-of-concept has been obtained in preclinical studies for therapeutic transdifferentiation. Specifically, several investigators have used viral vectors encoding lineage factors to transdifferentiate nonvascular cells into ECs. Based on our previous work that optimal activation of innate immune signaling can increase epigenetic plasticity, we have used this property of cells to systematically change their phenotype. This knowledge has permitted us to develop a small molecule cocktail that induces human fibroblasts to transdifferentiate into induced ECs. The human induced ECs are identical to genuine ECs as assessed by immunohistochemical markers, functional assays, and RNA seq transcriptional profiles. They can self-assemble into functional capillaries in vivo. In the murine model of PAD, injections of these cells into the ischemic hindlimb improve limb blood flow together with an increase in capillary density. Finally, the transdifferentiation cocktail can induce human fibroblasts to metamorphose into ECs in vivo, in a matrigel plug assay in immunodeficient mice. This proof-of-concept for vascular transdifferentiation in vivo provides encouragement for translational development.

Summary and Conclusion

It is disappointing that after extensive preclinical investigation, and after 2 decades of clinical trials of angiogenic or cell therapies, we have no Food and Drug Administration–approved therapies for PAD in either class. Nevertheless, we have gained great insights into the mechanisms of vascular regeneration and the response to ischemia. Furthermore, we have some understanding of the flaws in the preceding trials that may permit improved trial design in the future. Based on the foregoing information, we have the following recommendations:

1. The field needs a more practical regulatory roadmap. In particular, for CLI, the Food and Drug Administration has indicated that a demonstration of amputation-free survival will be required for approval. This is a high bar that discourages new drug development for this indication. Furthermore, this criterion does not recognize the real benefit of pain relief and wound healing for these individuals. Pain relief and wound healing in patients with CLI, in the absence of an adverse safety signal, should be approvable (and reimbursable) end points. A robust dialogue between regulatory bodies, physicians, and industry, with input from patients, is necessary to strike an appropriate balance between global risk (disease risk, potential risk of the therapy) and possible benefit.

2. There is a critical need for the application of novel imaging technologies to understand mechanisms of response and to indicate the likelihood of success. For example, MRI of perfusion and anatomy may provide evidence of enhanced perfusion and arteriogenesis. Molecular imaging with positron emission tomography probes may provide new insights into the distribution and fate of angiogenic agents or administered cells.

3. Preclinical models are challenged by the fact that the human leg is unique in form and function, and in the setting of PAD exists in a unique environment. Preclinical models may benefit by incorporating more features of PAD if this increases their predictive value. Investigators working with preclinical models should consider incorporating cardiovascular risk factors and chronic structural disease of the limb arteries into their models. Primate models remain the closest approximation to human atherosclerosis; however, they are difficult to use for financial, technical, and political reasons.

4. These improved models may provide critically needed information regarding the correct dose, duration, delivery method, for angiogenic or cell therapies. For example, should angiogenic therapy be targeted to the skeletal muscle, or directed along the course of the conduit vessels or collaterals?

5. Improvements to cell therapy will benefit from a more precise characterization of cellular subsets in the therapeutic product. At a basic level, it is necessary to understand which cell or cells being administered are the putative therapeutic agent, and to define the dose. A more comprehensive understanding of mechanisms of benefit and the contributions of different cellular subsets to the therapeutic effect are also required. Single cell analyses (eg, mass cytometry or RNA seq) may better define these subsets.

6. In clinical trials of cell therapies, a systematic approach to characterizing the study population and cell product, and the cell processing, dose, frequency, and delivery methods will likely add to the advancement of the field. A consensus statement on best practices for conducting and reporting cell therapy trials would improve the quality of studies, allow comparison of different approaches, and advance the field.

7. Angiogenic therapies have not yet fulfilled their early preclinical promise. This may be because of many factors including deficiencies in preclinical models, and insufficient information about drug dose, duration, and delivery. Newer strategies, such as therapeutic transdifferentiation, may revitalize this arena. In any event, in
the development of an effective angiogenic agent, one must also address safety concerns related to pathological angiogenesis. For example, many diabetic patients with PAD also have retinal neovascularization that might be adversely affected by an angiogenic therapy. Accordingly, it is likely that any angiogenic therapy (small molecules to cells) will be safer if its delivery is constrained in space and time.

8. In the meantime, lacking any approved angiogenic or cell therapy for PAD, the best way to enhance collateral formation and angiogenesis may be regular exercise. Because the patient with PAD typically has coexisting coronary artery disease, these individuals should be under the care of a cardiologist or vascular specialist, who can supervise a stress test to detect myocardial ischemia, and initiate medications to reduce cardiovascular risk, before implementing a supervised exercise program.

Disclosures
This work was supported in part by National Institutes of Health grants to J.P. Cooke (U01 HL100397, U01 HL099997, and U1MI HL113456). Dr Cooke is an inventor on patents owned by Stanford University related to the generation of nuclear reprogramming to HL113456). Dr Cooke is an employee of NeoStem, which is developing stem cell therapies for cardiovascular pluripotency and transdifferentiation. Dr Losordo is an employee of the University.


Cooke and Losordo

Gene and Cell Therapy for Limb Ischemia


